IMPL logo

Impel Pharmaceuticals (IMPL) Stock

Profile

Full Name:

Impel Pharmaceuticals Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

23 April 2021

Indexes:

Not included

Website:

http://impelpharma.com

Description:

Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle, Washington. On December 19, 2023, Impel Pharmaceuticals Inc, along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas.

Key Details

Price

-

Market Cap

-

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$12.65 M(+1794.01% YoY)

Annual EPS

-$4.53(+13.71% YoY)

PE Ratio

-

Annual ROE

-2546.09%

Annual Debt To Equity

-1.09

Beta

-

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Mar 22, 2024

Recent annual earnings:

Mar 22, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

15 Nov '22 Wedbush
Neutral
25 Aug '22 JonesTrading
Buy
18 May '21 Wedbush
Outperform
18 May '21 Guggenheim
Buy

Screeners with IMPL included

No data

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price All-time High

$26.13
IMPL price is currently at an all-time high

Price Analysts Target

$40.00
IMPL price is currently equal to the consensus analysts' forecast

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Revenue Estimate

$28.70 M
IMPL annual revenue is currently -55.92% lower than the consensus analysts' forecast

Annual Net Income 3-Year Change

-153.98%
IMPL annual net profit is down -153.98% over the past 3 years

Annual EPS 3-Year Change

-40.5%
IMPL annual earnings per share is down -40.5% over the past 3 years

Annual EPS Estimate

-$1.58
IMPL annual earnings per share is currently +186.71% higher than the consensus analysts' forecast

Annual Gross Profit

$6.16 M
IMPL annual gross profit is $6.16 million

Annual Operating Profit

-$83.18 M
IMPL annual operaing income is -$83.18 million

Annual Operating Profit 3-Year Change

-100.13%
IMPL annual operaing income is down -100.13% over the past 3 years

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual ROE

-2546.09%
IMPL annual return on equity is -2546.09%

Annual ROA

-114.03%
IMPL annual return on assets is -114.03%

Annual EBIT

-$83.18 M
IMPL annual earnings before interest & taxes is -$83.18 million

Annual EBITDA

-$83.18 M
IMPL annual earnings before interest, taxes, depreciation & amortization is -$83.18 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Quick Ratio

3.22
IMPL annual quick ratio is 3.22

Annual Current Ratio

3.60
IMPL annual current ratio is 3.60

Annual Total Assets

$88.55 M
IMPL annual total assets is $88.55 million

Annual Current Assets

$79.81 M
IMPL annual total current assets is $79.81 million

Annual Total Liabilities

$132.71 M
IMPL annual total liabilities is $132.71 million

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual CFO 3-Year Change

-156.64%
IMPL annual cash flow from operations is down -156.64% over the past 3 years

Annual CFI 3-Year Change

+9.59%
IMPL annual cash flow from investing activities is up +9.59% over the past 3 years

Annual CFF 3-Year Change

+321142.86%
IMPL annual cash flow from financing activities is up +321142.86% over the past 3 years

Annual CAPEX

$1.38 M
IMPL annual capital expenditures is $1.38 million

Annual FCF

-$95.02 M
IMPL annual free cash flow is -$95.02 million

Annual FCF 3-Year Change

-149.98%
IMPL annual free cash flow is down -149.98% over the past 3 years

Institutional Ownership

Similar stocks

Why Is Impel Pharmaceuticals (IMPL) Stock Up 32% Today?
Why Is Impel Pharmaceuticals (IMPL) Stock Up 32% Today?
Why Is Impel Pharmaceuticals (IMPL) Stock Up 32% Today?
IMPL
InvestorPlace08 September 2023

Impel Pharmaceuticals (NASDAQ: IMPL ) stock is on the rise Friday after the company announced an amended credit agreement with Oaktree Fund Administration. This new credit agreement has Impel Pharmaceuticals obtaining a loan of $121.5 million from new and existing investors.

Why Is Impel Pharmaceuticals (IMPL) Stock Down 35% Today?
Why Is Impel Pharmaceuticals (IMPL) Stock Down 35% Today?
Why Is Impel Pharmaceuticals (IMPL) Stock Down 35% Today?
IMPL
InvestorPlace16 August 2023

Impel Pharmaceuticals (NASDAQ: IMPL ) stock is falling on Wednesday after the biopharmaceutical company failed to file its earnings report on time. According to a filing with the Securities and Exchange Commission (SEC), several issues kept Impel Pharmaceuticals from filing in a timely manner.

Impel Pharmaceuticals Inc. (IMPL) Q4 2022 Earnings Call Transcript
Impel Pharmaceuticals Inc. (IMPL) Q4 2022 Earnings Call Transcript
Impel Pharmaceuticals Inc. (IMPL) Q4 2022 Earnings Call Transcript
IMPL
Seeking Alpha24 March 2023

Impel Pharmaceuticals Inc. (NASDAQ:IMPL ) Q4 2022 Earnings Conference Call March 24, 2023 8:30 AM ET Company Participants Adrian Adams - Chairman & Chief Executive Officer Leonard Paolillo - Chief Commercial Officer Rajiv Amin - Controller & Interim Chief Financial Officer Conference Call Participants Stacy Ku - Cowen Eddie Hickman - Guggenheim Partners Laura Chico - Wedbush Sean Kim - JonesTrading Operator Good morning, ladies and gentlemen and welcome to Impel Pharmaceuticals Fourth Quarter and Full Year 2022 Earnings and Business Update Conference Call. [Operator Instructions] As a reminder, today's conference is being recorded.

Impel Pharmaceuticals Inc. (IMPL) Reports Q4 Loss, Tops Revenue Estimates
Impel Pharmaceuticals Inc. (IMPL) Reports Q4 Loss, Tops Revenue Estimates
Impel Pharmaceuticals Inc. (IMPL) Reports Q4 Loss, Tops Revenue Estimates
IMPL
Zacks Investment Research24 March 2023

Impel Pharmaceuticals Inc. (IMPL) delivered earnings and revenue surprises of 6.73% and 23.35%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

FAQ

  • What is the primary business of Impel Pharmaceuticals?
  • What is the ticker symbol for Impel Pharmaceuticals?
  • Does Impel Pharmaceuticals pay dividends?
  • What sector is Impel Pharmaceuticals in?
  • What industry is Impel Pharmaceuticals in?
  • What country is Impel Pharmaceuticals based in?
  • When did Impel Pharmaceuticals go public?
  • Is Impel Pharmaceuticals in the S&P 500?
  • Is Impel Pharmaceuticals in the NASDAQ 100?
  • Is Impel Pharmaceuticals in the Dow Jones?
  • When was Impel Pharmaceuticals's last earnings report?
  • When does Impel Pharmaceuticals report earnings?
  • Should I buy Impel Pharmaceuticals stock now?

What is the primary business of Impel Pharmaceuticals?

Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle, Washington. On December 19, 2023, Impel Pharmaceuticals Inc, along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas.

What is the ticker symbol for Impel Pharmaceuticals?

The ticker symbol for Impel Pharmaceuticals is NASDAQ:IMPL

Does Impel Pharmaceuticals pay dividends?

No, Impel Pharmaceuticals does not pay dividends

What sector is Impel Pharmaceuticals in?

Impel Pharmaceuticals is in the Healthcare sector

What industry is Impel Pharmaceuticals in?

Impel Pharmaceuticals is in the Biotechnology industry

What country is Impel Pharmaceuticals based in?

Impel Pharmaceuticals is headquartered in United States

When did Impel Pharmaceuticals go public?

Impel Pharmaceuticals's initial public offering (IPO) was on 23 April 2021

Is Impel Pharmaceuticals in the S&P 500?

No, Impel Pharmaceuticals is not included in the S&P 500 index

Is Impel Pharmaceuticals in the NASDAQ 100?

No, Impel Pharmaceuticals is not included in the NASDAQ 100 index

Is Impel Pharmaceuticals in the Dow Jones?

No, Impel Pharmaceuticals is not included in the Dow Jones index

When was Impel Pharmaceuticals's last earnings report?

Impel Pharmaceuticals's most recent earnings report was on 22 March 2024

When does Impel Pharmaceuticals report earnings?

The date for Impel Pharmaceuticals's next earnings report has not been announced yet

Should I buy Impel Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions